Company intelligence / Profile preview
Sona Nanotech Inc.
Halifax, Nova Scotia, Canadasonanano.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Sona Nanotech’s Targeted Hyperthermia Therapy has demonstrated strong efficacy in multiple preclinical studies. In models of melanoma and breast cancer as well as immunotherapy-resistant colon cancer ("cold" tumors), the therapy shrank tumors and activated a robust immune response. The company’s gold nanorods are uniquely biocompatible due to their CTAB-free synthesis. First-in-human feasibility studies are being planned.
- Therapeutic areas
- OncologyNeurologyInfectious Diseases
- Modalities
- Gold nanorods (GNRs) for photothermal therapy and diagnosticsnanoparticle-based drug delivery
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Collaborations with Dalhousie University Medical School for preclinical researchadvisory input from leading U.S. academic medical centers
Beyond the preview
Go deeper on Sona Nanotech Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sona Nanotech Inc..